Zoetis Inc. (ETR:ZOE)

Germany flag Germany · Delayed Price · Currency is EUR
103.12
-0.56 (-0.54%)
At close: Dec 5, 2025
-38.70%
Market Cap 45.50B
Revenue (ttm) 8.01B
Net Income (ttm) 2.26B
Shares Out n/a
EPS (ttm) 5.06
PE Ratio 20.14
Forward PE 18.28
Dividend 1.78 (1.73%)
Ex-Dividend Date Oct 31, 2025
Volume 1,348
Average Volume 1,000
Open 103.00
Previous Close 103.68
Day's Range 102.74 - 103.70
52-Week Range 101.00 - 172.60
Beta 0.96
RSI 33.85
Earnings Date Feb 13, 2026

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]

Sector Healthcare
Founded 1950
Employees 13,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ZOE
Full Company Profile

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD Financial Statements

News

Zoetis (ZTS) Gains Health Canada Approval for New Cat Osteoarthritis Treatment

Zoetis (ZTS) Gains Health Canada Approval for New Cat Osteoarthritis Treatment

15 hours ago - GuruFocus

Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteo...

16 hours ago - Business Wire

Zoetis Inc at Piper Sandler Healthcare Conference Transcript

Zoetis Inc at Piper Sandler Healthcare Conference Transcript

1 day ago - GuruFocus

Zoetis (ZTS) Up 1.7% Since Last Earnings Report: Can It Continue?

Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

1 day ago - Nasdaq

BTIG Reiterates Buy Rating for Zoetis (ZTS) with $160 Target Price | ZTS Stock News

BTIG Reiterates Buy Rating for Zoetis (ZTS) with $160 Target Price | ZTS Stock News

2 days ago - GuruFocus

Zoetis Inc To Host Innovation Webcast Transcript

Zoetis Inc To Host Innovation Webcast Transcript

3 days ago - GuruFocus

Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation - Slideshow

2025-12-02. The following slide deck was published by Zoetis Inc.

3 days ago - Seeking Alpha

S&P 500 Movers: ZTS, APP

In early trading on Tuesday, shares of Applovin topped the list of the day's best performing components of the S&P 500 index, trading up 6.4%. Year to date, Applovin registers a 104.8% gain. And the w...

3 days ago - Nasdaq

Zoetis Inc. (ZTS) Announces Upcoming Innovation Webcast

Zoetis Inc. (ZTS) Announces Upcoming Innovation Webcast

3 days ago - GuruFocus

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&...

3 days ago - Wallstreet:Online

Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update...

3 days ago - Business Wire

Top 15 High-Growth Dividend Stocks For December 2025

The Top 15 High-Growth Dividend Stocks for December 2025 offer a 1.58% yield and 20.97% five-year dividend growth, appearing 33% undervalued. The watchlist's goal is a 12% long-term CAGR, with Novembe...

3 days ago - Seeking Alpha

2 Stocks to Buy Near Their 52-Week Lows

Not all stocks are soaring, but that may provide opportunity for long-term investors. Pinterest is hitting a lot of the right notes that could set it up for long-term success.

4 days ago - The Motley Fool

Zoetis (ZTS) Gains EU Approval for Lenivia in Canine Osteoarthritis

Zoetis (ZTS) Gains EU Approval for Lenivia in Canine Osteoarthritis

9 days ago - GuruFocus

Zoetis (ZTS) Gains EU Approval for Canine Osteoarthritis Therapy Lenivia

Zoetis (ZTS) Gains EU Approval for Canine Osteoarthritis Therapy Lenivia

9 days ago - GuruFocus

Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the re...

9 days ago - Business Wire

Zoetis Receives European Commission Marketing Authorization for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs...

9 days ago - Wallstreet:Online

Paul Harris' Top Picks: FirstService, Zoetis & Adobe

Paul Harris, partner and portfolio manager at Harris Douglas Asset Management, shares his top stock picks to watch in the market.

11 days ago - BNN Bloomberg

Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst

As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation. ZTS shares a...

14 days ago - Benzinga

Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst

As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.

14 days ago - Benzinga

Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stock News

Zoetis (ZTS) Receives New Analyst Rating from Keybanc | ZTS Stock News

14 days ago - GuruFocus

Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc

Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc

15 days ago - GuruFocus

A Look Into Zoetis Inc's Price Over Earnings

In the current market session, Zoetis Inc. (NYSE: ZTS) price is at $117.53, after a 0.38% spike. However, over the past month, the stock fell by 20.42% , and in the past year, by 34.17% . Shareholder...

15 days ago - Benzinga